BREAST CANCER

“In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo,”

Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

Once the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

In an interview with Targeted Oncology, Ann H. Partridge, MD, MPH, discussed the response to neoadjuvant chemotherapy among patients with ER-positive, HER2-negative breast cancer and how the 21-gene Breast Recurrence Score aids in the prediction of response for this treatment.

Based on phase 3 findings, F-627 appears at least as efficacious and safe as pegfilgrastim, which is the current standard of care, demonstrating strong and durable benefit in patients with breast cancer.

In an interview with Targeted Oncology, Julie R. Gralow, MD, discussed the findings from the KAITLIN study of T-DM1 in early-stage breast cancer.

“By retrospectively analyzing data from the adjuvant BIG 2-98 trial, we demonstrated that overweight and obese patients treated with a docetaxel-based chemotherapy regimen presented with a worse disease-free and overall survival compared with average weight patients treated with the same chemotherapy regimen."

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

"The results of the global phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC."

In New York City, high cases of COVID-19 continue to be reported with a high prevalence among racial and ethnic minorities.

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.

"We can potentially offer a new treatment option for patients with high-risk HR-positive, HER2-negative early breast cancer. "

“With demonstration of efficacy in biomarker-selected BRCA-like phenotype triple-negative breast cancer, the results of this trial are a very positive step toward expanding the role of PARP inhibitors beyond germline BRCA in breast cancer."